BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...2018. ViralClear Pharmaceuticals Inc. said Tony Zook will join the board. Zook was president of MedImmune Inc....
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

...a letter Mott sent to BioCentury. Prior to NEA, Mott had a 16-year tenure at MedImmune Inc....
BioCentury | Dec 4, 2019
Company News

Audentes takeout signals pharma's continued interest in gene therapy manufacturing

...JNJ's Janssen unit is collaborating with MeiraGTx to develop gene therapies for ophthalmic indications; AZ's MedImmune Inc....
BioCentury | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

...joined as CSO. He was VP of R&D and head of oncology research at the MedImmune Inc....
BioCentury | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

...Inc. division of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), as well as a veteran of MedImmune Inc....
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...investment from Life Sciences Fund Amsterdam, and revenues from licensing deals with partners including the MedImmune Inc....
BioCentury | Apr 7, 2017
Finance

Right place, right time

...and CEO Peter Greenleaf and CSO Peter Kiener had worked with Mott and Machielse at MedImmune Inc....
BioCentury | Aug 10, 2015
Company News

Kyowa Hakko Kirin, AstraZeneca deal

...and commercialize benralizumab outside of Japan and certain Asian countries through its 2007 acquisition of MedImmune Inc....
BioCentury | Jul 28, 2014
Finance

Highlights of weekly biotech stock moves

...Flow Advaxis Inc. (NASDAQ:ADXS) gained $0.28 (10%) to $2.92 last week after partnering with the MedImmune Inc....
BioCentury | Jul 23, 2014
Company News

Advaxis, AZ in immunotherapy deal

...Advaxis Inc. (NASDAQ:ADXS) and the MedImmune Inc. unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered in a non-exclusive...
Items per page:
1 - 10 of 706
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...2018. ViralClear Pharmaceuticals Inc. said Tony Zook will join the board. Zook was president of MedImmune Inc....
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

...a letter Mott sent to BioCentury. Prior to NEA, Mott had a 16-year tenure at MedImmune Inc....
BioCentury | Dec 4, 2019
Company News

Audentes takeout signals pharma's continued interest in gene therapy manufacturing

...JNJ's Janssen unit is collaborating with MeiraGTx to develop gene therapies for ophthalmic indications; AZ's MedImmune Inc....
BioCentury | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

...joined as CSO. He was VP of R&D and head of oncology research at the MedImmune Inc....
BioCentury | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

...Inc. division of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), as well as a veteran of MedImmune Inc....
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...investment from Life Sciences Fund Amsterdam, and revenues from licensing deals with partners including the MedImmune Inc....
BioCentury | Apr 7, 2017
Finance

Right place, right time

...and CEO Peter Greenleaf and CSO Peter Kiener had worked with Mott and Machielse at MedImmune Inc....
BioCentury | Aug 10, 2015
Company News

Kyowa Hakko Kirin, AstraZeneca deal

...and commercialize benralizumab outside of Japan and certain Asian countries through its 2007 acquisition of MedImmune Inc....
BioCentury | Jul 28, 2014
Finance

Highlights of weekly biotech stock moves

...Flow Advaxis Inc. (NASDAQ:ADXS) gained $0.28 (10%) to $2.92 last week after partnering with the MedImmune Inc....
BioCentury | Jul 23, 2014
Company News

Advaxis, AZ in immunotherapy deal

...Advaxis Inc. (NASDAQ:ADXS) and the MedImmune Inc. unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered in a non-exclusive...
Items per page:
1 - 10 of 706